Clinical Trial Detail

NCT ID NCT03237780
Title Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

urethra transitional cell carcinoma

Therapies

Atezolizumab

Atezolizumab + Eribulin

Age Groups: senior adult

No variant requirements are available.